Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance

@inproceedings{Rezende2013DeterminationOS,
  title={Determination of serum levels of imatinib mesylate in patients with
chronic myeloid leukemia: validation and application of a new analytical method to
monitor treatment compliance},
  author={Vin{\'i}cius Marcondes Rezende and Ariane Julio Rivellis and Melissa Medrano Gomes and Felipe Augusto D{\"o}rr and Mafalda Megumi Yoshinaga Novaes and Luciana Nardinelli and Ariel Lais de Lima Costa and Dalton de Alencar Fisher Chamone and Israel Bendit},
  booktitle={Revista brasileira de hematologia e hemoterapia},
  year={2013}
}
OBJECTIVE The goal of this study was to monitor imatinib mesylate therapeutically in the Tumor Biology Laboratory, Department of Hematology and Hemotherapy, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (USP). A simple and sensitive method to quantify imatinib and its metabolite (CGP74588) in human serum was developed and fully validated in order to monitor treatment compliance. METHODS The method used to quantify these compounds in serum included protein… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Current treatment strategies in chronic myeloid leukemia.

  • Current opinion in hematology
  • 2012
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Pretheraputic expression of hoct1 gene predict a complete molecular response to imatinib mesylate in chronic myeloid leukemia chronic phase

J Nardelli, SS Sanabani, +3 authors MM Novaes
  • Acta Haematol
  • 2012
VIEW 1 EXCERPT